Medivation/Pfizer initiate Ph III Dimebon trial

World drug giant Pfizer and USA-based Medivation have initiated a 12-month, Phase III trial of Dimebon (dimebolin) when added to ongoing  treatment with mild-to-moderate Alzheimer's disease patients taking  donepezil HCI.

The CONCERT study is part of a broad, late-stage development program for  Dimebon. The study builds on data from a small-scale safety and  tolerability trial of the drug added to donepezil, which found the  combination to be well tolerated.

CONCERT is designed to complement previous and ongoing studies by  further evaluating the efficacy of Dimebon. The Phase III program also  includes the confirmatory six-month CONNECTION study, which is designed  to evaluate the safety and efficacy of Dimebon monotherapy in patients  with mild-to-moderate AD and builds on the results of the first pivotal  trial of the compound.